Ekf Diagnostics Share Discussion Threads

[sirshagalot] 18/1/2018 18:03

Yes sell on news and buy into dip this has a lot going for it .

[wan] 11/1/2018 07:23

Another solid trading update today confirming a very healthy 2017, and a healthy increase in the net cash position to £6.8m.

sTNFR spin-out offers interesting upside considering it is valued at nil! That aside I think we will see some good growth opportunities realised during 2018.

[wan] 07/11/2017 07:38

Some large volumes of late, so I assume we will see RNS's accordingly.

I am confident that EKF will deliver on their outlook in terms of sales growth. Over the medium term, the following could see a big uplift in revenues from the US - "Medium-term growth opportunities from new registrations and customers: – Draft agreements in place with OEM partners in USA for DiaSpect Tm and Quo-Test A1c"

New EKF product introduction at Medica (next week) -

Article by CHRIS MIDDLETON
06/11/2017

Cardiff-based EDK Diagnostics is set to introduce a new product at Medica – “POC Connect” – a data management mobile app that enables the storage, access and transmission of haemoglobin results directly from EFK Diagnostic’s DiaSpect Tm haemoglobin analyzer to a smartphone via Bluetooth® technology.

The POC Connect mobile app is the world’s first mobile data management solution for a reagent-free haemoglobin testing device.

POC Connect is ideal for mobile health checks and anaemia screening in countries where environmental conditions may be challenging or where there may not be consistent internet availability.

Katja Lemburg, Hematology Global Product Manager from EKF Diagnostics said, “Within developing countries, there is a growing demand for mobile data management solutions due to the lack of internet-based communications infrastructure and the by-passing of more traditional based middleware providers.

“So this new development is an ideal solution where internet connections can be unreliable. Mobile health care services are on the increase so we hope to see our smartphone-based connectivity solution playing a part in this growing trend.

“We’re looking forward to unveiling this world first at Medica this year.”

Full article -

[wan] 05/11/2017 07:35

An excellent article -

Diagnosing Diabetes: The Value of HbA1c Testing
ARTICLE Nov 03, 2017 | By Anna MacDonald, Editor for Technology Networks

We spoke to EKF’s Gavin Jones to learn more about the current methods of diabetes diagnosis and monitoring, the advantages of HbA1C testing, and how testing may change in the future.

Where do you see the future of diabetes diagnostics headed?

There are a number of improvements in the use of HbA1c for the monitoring of diabetes currently being considered, recently CAP (College of American Pathologists) and NGSP (National Glycohemoglobin Standardization Program) agreed that they should tighten the criteria for the HbA1c survey to ±5% beginning in 2019. Currently the requirement is to meet ±6% to the reference method, this change will undoubtedly reduce the number of available HbA1c methods on the market and improve the quality of results of those that remain, leading to a more controlled and consistent testing environment. Whilst seen by some manufacturers as a challenging criteria to meet, this change can only be looked upon as a positive improvement to the accuracy and precision of HbA1c monitoring on an industry-wide scale.

Point-of-care testing

As POC HbA1c testing becomes more accepted, it will start to become a more viable option for the diagnosis of diabetes. There are already POC HbA1c methods that meet the same criteria for diagnosis as lab systems, and with the increased accuracy being imposed upon the industry, the argument for only allowing lab systems to be used for diagnosis is slipping away. The benefits of POC HbA1c measurement, both clinically and from a patient-engagement perspective, cannot be ignored. It is only a matter of time before this becomes the accepted method for diabetes diagnosis.

Full story (a very worthwhile read) -

[wan] 02/11/2017 16:36

2nd November 2017
EKF Diagnostics, the global in vitro diagnostics company, announces that its Stanbio Chemistry Procalcitonin (PCT) LiquiColor® assay has been FDA cleared and validated for use on Beckman AU 480, 680 and 5800 clinical chemistry analyzers. EKF is pleased to confirm the immediate availability of a user defined application (UDA) for running this 10 minute test for bacterial infection and sepsis on these Beckman AU analyzers.

[wan] 26/10/2017 08:31

Sober reading, but there is a lot of growth to be realised -

26th October 2017

Novo Nordisk warns diabetes costs threaten to overwhelm healthcare
Pharma chief says annual bill could hit $1tn by 2045



Only about 6 per cent of all people with diabetes today were being so effectively treated as to avoid the risk of potentially life-threatening, late-stage complications. He added: “We are far from having identified all the people with diabetes and [got] all of them on treatment so we see that as ample opportunity for us to still grow.”

Full story -

[wan] 18/10/2017 11:35

MW...Sorry to learn that.

HbA1c can be used as a diagnostic test for diabetes and as a screening test for people at high risk of diabetes. But it is also a very important test for people managing diabetes, as any reduction in HbA1c levels will have beneficial effects with regard to reducing the risk of developing complications (nerve damage, eye disease, kidney disease and heart disease).

One thing that I have always thought regarding type 1 diabetes, is that should there be a medical breakthrough preventing individuals from having to inject insulin (and thereby not having to regularly check/test glucose levels), regular HbA1c testing is very likely to still be recommended.

[mw8156] 18/10/2017 11:10

wan

your post accords with my own experience, fasting blood glucose was all right just when I was diagnosed but HbA1c was clearly abnormal as was the glucose tolerance test, though one can't extrapolate from n=1!

[wan] 18/10/2017 11:04

9degrees...Yes I did note that, however, 60% of the world's diabetic population is Asian, so despite the limitations of the study from a global perspective, the findings are still relevant. It's an unfortunate fact that Asians are far more likely to develop diabetes compared with people from white European backgrounds.

China has the largest diabetic population in the world, followed by India, the US is a distant 3rd!

Why are Asians at Higher Risk?

Studies have shown that Asians are at higher risk of developing type 2 diabetes, when compared with people of European ancestry.1 Asians are more likely to develop the disease even at a lower BMI. This means that even though some Asian populations currently have a lower prevalence of overweight and obese individuals than populations in the West, they have a disproportionately high percentage of people with diabetes.1 Currently, 60% of the world’s diabetic population is Asian.
hxxp://asiandiabetesprevention.org/what-is-diabetes/why-are-asians-higher-risk

[wan] 18/10/2017 11:04

Double post!

[9degrees] 18/10/2017 10:39

Wan - all people tested were Vietnamese - not a typical western diet and lifestyle I wonder if that makes a difference ??

[wan] 18/10/2017 08:32

I noted the following recently -

October 06, 2017
HbA1c vs Fasting Plasma Glucose for Prediabetes, Diabetes Diagnosis

Patients with undiagnosed diabetes screened via fasting plasma glucose (FPG) may remain undiagnosed vs patients screened via hemoglobin A1c (HbA1c) blood test, according to a study published in PLOS ONE.

The investigators concluded that HbA1c testing has a higher sensitivity for identifying patients at risk for diabetes vs FPG, and therefore may have a greater impact on the diagnoses, cost, burden, and treatment of patients with diabetes.


Full story -

[wan] 14/10/2017 07:07

Ortho Clinical, EKF Expand Access to Ketoacidosis Assay

Oct 11, 2017
NEW YORK – Ortho Clinical Diagnostics and EKF Diagnostic today announced a deal to provide patients expanded access to EKF's beta-hydroxybutyrate assay for the diagnosis of ketoacidosis.

Full story -

[wan] 11/9/2017 08:01

Excellent progress still being made, and given the 'long' list of new product registrations being pursued (amongst other things), it would appear there is a lot more growth and progress to come!

[sirshagalot] 09/8/2017 19:08

charts still indicate more upside

[9degrees] 07/8/2017 11:35

zwanzigger reduced his holdings

[tawnyport] 18/7/2017 12:34

Kestelmill - I agree re the acquisition de-focus. However, just to qualify that - the only failed acquisition (out of 8) was Selah. This failed because the management team was not experienced enough (and arguably the industry was not ready) to move into molecular diagnostics alongside traditional point of care diagnostics.

[tawnyport] 18/7/2017 12:29

I would hardly classify a new NED as a new team.

Anyway, the crux here is that a new non-exec Chairman is in place and he is an experienced, focussed, and successful individual - he is the one who has given the company a new lease of life by concentrating on an exit-based trade sale strategy, one which the previous Chairman arguably was unable to consummate.

[wan] 18/7/2017 12:15

So we have more than just one new team member, arguably a different team, and perhaps most importantly, a new focus.

[tawnyport] 18/7/2017 11:56

Wan - Julian Baines has been there as CEO since the Company listed in 2010; Richard Evans has been COO/CFO (and previously just CFO) since 2011.

Adam has been an NED since 2010 and Carl was appointed an NED earlier this year.

[wan] 18/7/2017 11:36

Tawnyport...I suggest you check the RNS announcements then, along with the following EKF investor page -
hxxps://www.ekfdiagnostics.com/investors-directors-advisors.html

[tawnyport] 18/7/2017 11:17

Wan - the only new management team member is Chris Mills; he replaced David Evans (who was succeeded by Ron Zwanziger for a short period).

[wan] 17/7/2017 16:25

Large volume today!

[wan] 06/7/2017 17:04

Kestlemill...No it's not the same management team you refer to. EKF have a new management team in place, it has been restructured, refocused and refinanced, hence the significant improvements that are now flowing through.